Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CheckMate -67T is the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics, efficacy and safety vs. its intravenous...
Bristol Myers Squibb announced the first disclosure of data from the Phase 3 CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo co-formulated with Halozyme?s proprietary...
PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...
1. In this randomized controlled trial, replacing biomass stoves with those using liquefied petroleum gas (LPG) during pregnancy did not reduce stunting in infants at one year despite reductions in household air pollution. 2. There was no appreciable difference in stunting in infants at six months between the biomass cookstove and liquefied petroleum gas cookstove
Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits...